Intelligence Feed event · Equity · 2026-08-04

    Supernus Pharmaceuticals to Merge with Indivior in All-Stock Deal

    Question

    Supernus Pharmaceuticals to Merge with Indivior in All-Stock Deal

    Direct answer

    Supernus and Indivior are combining to create a more robust mid-cap pharmaceutical player. The deal focuses on expanding the portfolio of FDA-approved treatments and streamlining operations. The initial market enthusiasm faded, suggesting investors are waiting for more detail on the integration timeline and long-term growth prospects of the combined entity.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Supernus Pharmaceuticals to Merge with Indivior in All-Stock Deal”, revision 1, evidence through 2026-08-04. https://marketontology.com/market-events/2026-08-04/supernus-pharmaceuticals-to-merge-with-indivior-in-all-stock-deal-777246

    EQUITY
    Supernus Pharmaceuticals to Merge with Indivior in All-Stock Deal
    Supernus and Indivior are combining to create a more robust mid-cap pharmaceutical player. The deal focuses on expanding the portfolio of FDA-approved treatments and streamlining operations. The initial market enthusiasm faded, suggesting investors are waiting for more detail on the integration timeline and long-term growth prospects of the combined entity.
    SUPNINDV
    Impact
    73
    AUG 4
    SIG
    90%
    SUPNINDV
    Supernus Pharmaceuticals to Merge with Indivior in All-Stock Deal
    Supernus and Indivior are combining to create a more robust mid-cap pharmaceutical player. The deal focuses on expanding the portfolio of FDA-approved treatments and streamlining operations. The initial market enthusiasm faded, suggesting investors are waiting for more detail on the integration timeline and long-term growth prospects of the combined entity.
    → Consolidation in the pharmaceutical sector to achieve scale and cost efficiencies.
    Impact
    Supernus and Indivior are combining to create a more robust mid-cap pharmaceutical player. The deal focuses on expanding the portfolio of FDA-approved treatments and streamlining operations. The initial market enthusiasm faded, suggesting investors are waiting for more detail on the integration timeline and long-term growth prospects of the combined entity.
    Affected
    SUPNINDV
    Transmission
    Consolidation in the pharmaceutical sector to achieve scale and cost efficiencies.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month